Research
Molecular
Inhibiting the Group-specific component (GC) gene may provide a novel therapeutic target for treating metabolic diseases.
Practitioners may consider exploring GC inhibition as a treatment option for metabolic diseases.
StrongSupportsmedium confidence
GC therefore represents a promising novel therapeutic target for metabolic diseases.
Why this rating
The claim is supported by studies of GC-null humans and mice, indicating safety and potential benefits.
Source
On the potential of group-specific component (GC) inhibition for treating metabolic disease
Richard Gill et al. · Metabolism and Target Organ Damage · 2026
DOI 10.20517/mtod.2025.195
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →